For Patients and Caregivers

Helping your SMA patients choose the right formulation

Quick links

Oral formulations
Administration & storage considerations
FAQs

Evrysdi has 2 oral, non-invasive formulations, providing your eligible patients with more flexibility1

Patients must be ≥2 years of age and weigh ≥20 kg (44 lb) to take Evrysdi tablets. Tablet dispersion cannot be used in a gastrostomy or nasogastric tube.

Liquid and tablet formulations offer options that fit individual patient needs

  Liquid Tablet
Eligibility Patients of any age or weight Patients must be ≥2 years of age and weigh ≥20 kg (44 lb)
Administration Taken via oral syringe Can be swallowed whole with water or dispersed with non‑chlorinated drinking water (eg, filtered water, bottled water)
Storage Refrigerate 36°F to 46°F (2°C to 8°C) Store at room temperature, 68°F to 77°F (20°C to 25°C)
Use with G- or NG-tube Yes No
Obtaining Evrysdi Shipped directly to your patient's door through a specialty pharmacy

Splice-modifying technology in 2 oral formulations1,50

Evrysdi tablets deliver the same demonstrated efficacy and safety as the liquid

Evrysdi liquid and tablet formulations were proven to have comparable bioavailability

  • Studied in 48 participants
  • Both formulations provided comparable Evrysdi exposure over the course of 6 days
  • The safety profile of Evrysdi tablets was consistent with the safety profile of the liquid formulation

Administration and storage considerations1

  • If refrigeration is not available, Evrysdi liquid can be kept at room temperature up to 104°F (40°C) for a combined total of 5 days
  • Store Evrysdi tablets at room temperature, between 68°F to 77°F (20°C to 25°C). Excursions permitted between 59°F to 86°F (15°C to 30°C). Keep the bottle tightly closed in order to protect from moisture
  • In infants who are breastfed, Evrysdi liquid can be administered before or after breastfeeding. Evrysdi liquid cannot be mixed with formula or milk
  • Evrysdi liquid must be taken immediately after it is drawn up into the oral syringe. If Evrysdi is not taken within 5 minutes, Evrysdi should be discarded from the oral syringe and a new dose should be prepared
  • Advise patients to not chew, crush, or cut the Evrysdi tablet, or dissolve it on the tongue. Evrysdi tablets cannot be dispersed with anything other than room temperature bottled water
  • For patients who have difficulty swallowing the tablet whole, it can be dispersed with bottled water or the liquid formulation can be prescribed

Frequently asked questions

OBTAINING EVRYSDI

Advise patients or caregivers to contact their specialty pharmacy right away.

Evrysdi cannot be filled at a retail pharmacy. Evrysdi will be shipped directly to the patient’s home after it has been prepared by a specialty pharmacy.

ABOUT EVRYSDI LIQUID

Evrysdi lasts up to 64 days in the refrigerator at a temperature of 36°F to 46°F. After 64 days, any unused product should be discarded. The liquid solution should never be frozen and should be stored in an upright position with the cap tightly closed to avoid spillage. An expiration date will be indicated on the bottle after constitution by the pharmacist. When traveling, Evrysdi should be stored in an insulated cooler with ice packs at the recommended temperature of 36°F to 46°F.1

Evrysdi can be kept at room temperature up to 104°F (40°C) for a combined total of 5 days. It can be removed from, and returned to, a refrigerator. The total combined time out of refrigeration should not exceed 5 days. Any portion of Evrysdi that has been kept above 104°F (40°C) should be discarded.1

Each monthly shipment of Evrysdi will include ENFit® compatible oral/enteral syringes. The enclosed syringes will work with a variety of feeding tubes, including ENFit® feeding tubes. Specialty pharmacies stock the most common adapters so that syringes will work with most oral/enteral feeding tubes. If the specialty pharmacy does not provide the correct adapter, they will work with you, your patients, and/or caregivers to acquire the appropriate adapter.1,51

If a patient or caregiver notices leakage on any bottle, advise them to dry off the bottle with a dry paper towel then rinse the closed bottle with water. Store the bottle out of sight and out of reach of children. Call Genentech Product Complaints at 1-800-334-0290 to coordinate free replacement product and further instructions.

ABOUT EVRYSDI TABLET

A PA may be required for Evrysdi. Call the patient’s insurance provider or MySMA SupportTM at 833-EVRYSDI if you have questions about obtaining prior authorization for your patients. Once approved, a 30-day supply of Evrysdi tablets will be shipped directly to your patient’s door.

No. To avoid exposing the tablets to moisture, keep the tablets in their original container with the desiccant in the cap.1

Evrysdi tablets are 6.6 mm (0.25 in) in diameter and 4.1 mm (0.15 in) in height—about the size of a kernel of corn.5,52

The film coating on the tablet protects patients from the active ingredients until they are ingested and processed. Chewing, crushing, or otherwise breaking the film coating may result in extended exposure to the active ingredients before ingestion. The safety of Evrysdi tablets was studied when swallowed whole with water and when dispersed with bottled water. The safety of taking Evrysdi tablets any other way is unknown and therefore is not recommended.50,53

For complete information on how to take and administer Evrysdi, please refer your patients to the Instructions for Use for liquid and the Dosage and Administration section of the Prescribing Information for tablets

Understanding Evrysdi®️ and SMA support brochure icon

Overview of how Evrysdi is dosed

Download
Support resources icon

Connect with a Genentech representative

Get started

Access and reimbursement resources

MySMA Support offers helpful resources for your patients and practice

Learn more

One daily oral dose

Dosing tailored to your patients for liquid or tablet1

Learn more

SMA=spinal muscular atrophy.

Important Safety Information and Indication

Indication

EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Interactions with Substrates of MATE Transporters

  • Based on in vitro data, Evrysdi may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K, such as metformin
  • Avoid coadministration of Evrysdi with MATE (multidrug and toxin extrusion) substrates. If coadministration cannot be avoided, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug if needed

Pregnancy & Breastfeeding

  • Evrysdi may cause embryofetal harm when administered to a pregnant woman. In animal studies, administration of Evrysdi during pregnancy and/or lactation resulted in adverse effects on development. Advise pregnant women of the potential risk to the fetus
  • Pregnancy testing is recommended prior to initiating Evrysdi. Advise female patients to use contraception during treatment with Evrysdi and for at least 1 month after the last dose
  • There is a pregnancy exposure registry that monitors pregnancy and fetal/neonatal/infant outcomes in women exposed to Evrysdi during pregnancy. Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-833-760-1098 or visiting https://www.evrysdipregnancyregistry.com.
  • The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Evrysdi and any potential adverse effects on the breastfed infant

Potential Effects on Male Fertility

  • Counsel male patients that fertility may be compromised by treatment with Evrysdi. Male patients may consider sperm preservation prior to treatment

Most Common Adverse Reactions

  • The most common adverse reactions in later-onset SMA (incidence in at least 10% of patients treated with Evrysdi and more frequent than control) were fever, diarrhea, and rash
  • The most common adverse reactions in infantile-onset SMA were similar to those observed in later-onset SMA patients. Additionally, adverse reactions with an incidence of at least 10% were upper respiratory tract infection (including nasopharyngitis, rhinitis), lower respiratory tract infection (including pneumonia, bronchitis), constipation, vomiting, and cough
  • The safety profile for presymptomatic patients is consistent with the safety profile for symptomatic SMA patients treated with Evrysdi in clinical trials

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information.

    • Evrysdi® (risdiplam) Prescribing Information. Genentech, Inc.

      Evrysdi® (risdiplam) Prescribing Information. Genentech, Inc.

    • Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6(6):1-12.

      Poirier A, Weetall M, Heinig K, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018;6(6):1-12.

    • Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81(3):355-368.

      Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81(3):355-368.

    • Chiriboga CA, Bruno C, Duong T, et al. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. J Neurol. 2024;271(8):4871-4884.

      Chiriboga CA, Bruno C, Duong T, et al. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. J Neurol. 2024;271(8):4871-4884.

    • Data on file. Genentech USA, Inc.

      Data on file. Genentech USA, Inc.

    • Shababi M, Lorson CL, Rudnik‐Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease? J Anat. 2014;224(1):15-28.

      Shababi M, Lorson CL, Rudnik‐Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi‐organ disease? J Anat. 2014;224(1):15-28.

    • Aslesh T, Yokota T. Restoring SMN Expression: An overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells. 2022;11(3):417.

      Aslesh T, Yokota T. Restoring SMN Expression: An overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells. 2022;11(3):417.

    • Ojala KS, Reedich EJ, DiDonato CJ, Meriney SD. In search of a cure: the development of therapeutics to alter the progression of spinal muscular atrophy. Brain Sci. 2021;11(2):194.

      Ojala KS, Reedich EJ, DiDonato CJ, Meriney SD. In search of a cure: the development of therapeutics to alter the progression of spinal muscular atrophy. Brain Sci. 2021;11(2):194.

    • Cances C, Vlodavets D, Comi GP, et al; on behalf of ANCHOVY Working Group. Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet J Rare Dis. 2022;17(1):300.

      Cances C, Vlodavets D, Comi GP, et al; on behalf of ANCHOVY Working Group. Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet J Rare Dis. 2022;17(1):300.

    • Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020;109:12-19.

      Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. Pediatr Neurol. 2020;109:12-19.

    • Lipnick SL, Agniel DM, Aggarwal R, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS One. 2019;14(3):e0213680.

      Lipnick SL, Agniel DM, Aggarwal R, et al. Systemic nature of spinal muscular atrophy revealed by studying insurance claims. PLoS One. 2019;14(3):e0213680.

    • Mercuri E, Deconinck N, Mazzone ES, et al; on behalf of the SUNFISH Study Group. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH Part 2): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42-52.

      Mercuri E, Deconinck N, Mazzone ES, et al; on behalf of the SUNFISH Study Group. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH Part 2): A phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2022;21(1):42-52.

    • Finkel RS, Farrar MA, Servais L, et al. RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Presented at: Congress of the World Muscle Society (WMS); October 3-7, 2023; Charleston, SC.

      Finkel RS, Farrar MA, Servais L, et al. RAINBOWFISH: Primary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA). Presented at: Congress of the World Muscle Society (WMS); October 3-7, 2023; Charleston, SC.

    • Cure SMA State of SMA 2023 Report. Cure SMA. Accessed May 13, 2025. https://www.curesma.org/​wp-content/​uploads/​2024/​06/​9042024_State-of-SMA_vWeb.pdf

      Cure SMA State of SMA 2023 Report. Cure SMA. Accessed May 13, 2025. https://www.curesma.org/​wp-content/​uploads/​2024/​06/​9042024_State-of-SMA_vWeb.pdf

    • Wan HWY, Carey KA, D’Silva A, Kasparian NA, Farrar MA. “Getting ready for the adult world”: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14(1):74.

      Wan HWY, Carey KA, D’Silva A, Kasparian NA, Farrar MA. “Getting ready for the adult world”: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14(1):74.

    • Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018;128(8):3219-3227.

      Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018;128(8):3219-3227.

    • Voice of the patient report: spinal muscular atrophy (SMA). Cure SMA. Accessed May 13, 2025. https://curesma.wpengine.com/​​wp-content/​​uploads/​​2018/​​01/​​SMA-VoP-for-publication-1-22-2018.pdf

      Voice of the patient report: spinal muscular atrophy (SMA). Cure SMA. Accessed May 13, 2025. https://curesma.wpengine.com/​​wp-content/​​uploads/​​2018/​​01/​​SMA-VoP-for-publication-1-22-2018.pdf

    • Aponte Ribero V, Martí Y, Batson S, et al. Systematic literature review of the natural history of spinal muscular atrophy: motor function, scoliosis, and contractures. Neurology. 2023;101(21):e2103-e2113.

      Aponte Ribero V, Martí Y, Batson S, et al. Systematic literature review of the natural history of spinal muscular atrophy: motor function, scoliosis, and contractures. Neurology. 2023;101(21):e2103-e2113.

    • Schroth M, Deans J, Arya K, et al. Spinal muscular atrophy update in best practices: recommendations for diagnosis considerations. Neurol Clin Pract. 2024;14(4).

      Schroth M, Deans J, Arya K, et al. Spinal muscular atrophy update in best practices: recommendations for diagnosis considerations. Neurol Clin Pract. 2024;14(4).

    • Singh RN, Ottesen EW, Singh NN. The first orally deliverable small molecule for the treatment of spinal muscular atrophy. Neurosci Insights. 2020;15:1-11.

      Singh RN, Ottesen EW, Singh NN. The first orally deliverable small molecule for the treatment of spinal muscular atrophy. Neurosci Insights. 2020;15:1-11.

    • FDA approves Genentech’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. News Release. Genentech USA, Inc.; August 7, 2020. Accessed May 13, 2025. https://www.gene.com/​​media/​​press-releases/​​14866/​2020-08-07/​​fda-approves-genentechs-evrysdi-risdiplam

      FDA approves Genentech’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. News Release. Genentech USA, Inc.; August 7, 2020. Accessed May 13, 2025. https://www.gene.com/​​media/​​press-releases/​​14866/​2020-08-07/​​fda-approves-genentechs-evrysdi-risdiplam

    • Baranello G, Boespflug-Tanguy O, Darras BT, et al. FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). Supplement. Presented at: International Annual Congress of the World Muscle Society; September 28-October 2, 2020; Virtual.

      Baranello G, Boespflug-Tanguy O, Darras BT, et al. FIREFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). Supplement. Presented at: International Annual Congress of the World Muscle Society; September 28-October 2, 2020; Virtual.

    • Day JW, Annoussamy M, Baranello G, et al. SUNFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with type 2 or 3 spinal muscular atrophy (SMA). Presented at: 2020 Virtual SMA Conference; June 8-12, 2020; Virtual.

      Day JW, Annoussamy M, Baranello G, et al. SUNFISH Part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) treatment in patients with type 2 or 3 spinal muscular atrophy (SMA). Presented at: 2020 Virtual SMA Conference; June 8-12, 2020; Virtual.

    • Kletzl H, Cleary Y, Grimsey P, Gerber M, Scalco RS. Risdiplam: pharmacokinetic, pharmacodynamic, safety and efficacy exposure response analyses. Poster presented at: Cure SMA 2022 Research and Clinical Care Meeting; June 15-17, 2022; Anaheim, CA. 

      Kletzl H, Cleary Y, Grimsey P, Gerber M, Scalco RS. Risdiplam: pharmacokinetic, pharmacodynamic, safety and efficacy exposure response analyses. Poster presented at: Cure SMA 2022 Research and Clinical Care Meeting; June 15-17, 2022; Anaheim, CA. 

    • Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10)(suppl 1):915-923.

      Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10)(suppl 1):915-923.

    • Mercuri E, Deconinck N, Mazzone ES, et al; on behalf of the SUNFISH Study Group. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH Part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;21(1)(suppl 1):42-52.

      Mercuri E, Deconinck N, Mazzone ES, et al; on behalf of the SUNFISH Study Group. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH Part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;21(1)(suppl 1):42-52.

    • Mercuri E, Baranello G, Boespflug-Tanguy O, et al. Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2022;30(7):1945-1956.

      Mercuri E, Baranello G, Boespflug-Tanguy O, et al. Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol. 2022;30(7):1945-1956.

    • Darras BT, Boespflug-Tanguy O, Day JW, et al; on behalf of the FIREFISH Working Group. FIREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in infants with type 1 SMA. Presented at: Muscular Dystrophy Association Clinical and Scientific Conference; March 13-16, 2022; Nashville, TN.

      Darras BT, Boespflug-Tanguy O, Day JW, et al; on behalf of the FIREFISH Working Group. FIREFISH Parts 1 and 2: 24-month safety and efficacy of risdiplam in infants with type 1 SMA. Presented at: Muscular Dystrophy Association Clinical and Scientific Conference; March 13-16, 2022; Nashville, TN.

    • PTC Therapeutics announces FDA approval of Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy in adults and children 2 months and older. News Release. PTC Therapeutics. August 7, 2020. Accessed May 13, 2025. https://ir.ptcbio.com/​news-releases/​news-release-details/​ptc-therapeutics-announces-fda-approval-evrysditm-risdiplam

      PTC Therapeutics announces FDA approval of Evrysdi™ (risdiplam) for the treatment of spinal muscular atrophy in adults and children 2 months and older. News Release. PTC Therapeutics. August 7, 2020. Accessed May 13, 2025. https://ir.ptcbio.com/​news-releases/​news-release-details/​ptc-therapeutics-announces-fda-approval-evrysditm-risdiplam

    • Bérard C, Payan C, Hodgkinson I, Fermanian J; on behalf of the MFM Collaborative Study Group. A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15(7):463-470.

      Bérard C, Payan C, Hodgkinson I, Fermanian J; on behalf of the MFM Collaborative Study Group. A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15(7):463-470.

    • de Lattre C, Payan C, Vuillerot C, et al. Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013;94(11):2218-2226.

      de Lattre C, Payan C, Vuillerot C, et al. Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013;94(11):2218-2226.

    • Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C; MFM Spinal Muscular Atrophy Study Group. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil. 2013;94(8):1555-1561.

      Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C; MFM Spinal Muscular Atrophy Study Group. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil. 2013;94(8):1555-1561.

    • Duong T, Staunton H, Braid J, et al. A patient-centered evaluation of meaningful change on the 32-item motor function measure in spinal muscular atrophy using qualitative and quantitative data. Front Neurol. 2022;12:770423.

      Duong T, Staunton H, Braid J, et al. A patient-centered evaluation of meaningful change on the 32-item motor function measure in spinal muscular atrophy using qualitative and quantitative data. Front Neurol. 2022;12:770423.

    • Servais L, Oskoui M, Day JW, et al; on behalf of the SUNFISH Study Group. SUNFISH Parts 1 and 2: 4-year efficacy and safety of risdiplam in types 2 and 3 spinal muscular atrophy (SMA). Presented at: American Academy of Neurology; April 22-27, 2023; Boston, MA. 

      Servais L, Oskoui M, Day JW, et al; on behalf of the SUNFISH Study Group. SUNFISH Parts 1 and 2: 4-year efficacy and safety of risdiplam in types 2 and 3 spinal muscular atrophy (SMA). Presented at: American Academy of Neurology; April 22-27, 2023; Boston, MA. 

    • Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. Muscle Nerve. 2017;55(6):869-874.

      Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. Muscle Nerve. 2017;55(6):869-874.

    • Pera MC, Coratti G, Mazzone ES, et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019;59(4):426-430.

      Pera MC, Coratti G, Mazzone ES, et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019;59(4):426-430.

    • Day JW, Deconinck N, Mazzone E, et al. SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Poster presented at: Cure SMA Virtual Research & Clinical Care Meeting; June 9–11, 2021; Virtual.

      Day JW, Deconinck N, Mazzone E, et al. SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Poster presented at: Cure SMA Virtual Research & Clinical Care Meeting; June 9–11, 2021; Virtual.

    • Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915-923.

      Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915-923.

    • Mazurkiewicz-Bełdzińska M, Baranello G, Boespflug-Tanguy O, et al; on behalf of the FIREFISH Study Group. FIREFISH Parts 1 and 2: 5-year efficacy and safety of risdiplam in type 1 SMA. Roche USA, Inc.; 2024. Presented at: Cure SMA; June 6-9, 2024; Austin, Texas.

      Mazurkiewicz-Bełdzińska M, Baranello G, Boespflug-Tanguy O, et al; on behalf of the FIREFISH Study Group. FIREFISH Parts 1 and 2: 5-year efficacy and safety of risdiplam in type 1 SMA. Roche USA, Inc.; 2024. Presented at: Cure SMA; June 6-9, 2024; Austin, Texas.

    • Hammersmith Infant Neurological Examination. UNM Health. Accessed May 13, 2025. https://unmhealth.org/​services/​development-disabilities/​programs/​other-disability-programs/​cerebral-palsy-taskforce/​_media/​hammersmith-infant-neurological-exam.pdf.

      Hammersmith Infant Neurological Examination. UNM Health. Accessed May 13, 2025. https://unmhealth.org/​services/​development-disabilities/​programs/​other-disability-programs/​cerebral-palsy-taskforce/​_media/​hammersmith-infant-neurological-exam.pdf.

    • Prior TW, Leach ME, Finanger EL. Spinal Muscular Atrophy. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; February 24, 2000.

      Prior TW, Leach ME, Finanger EL. Spinal Muscular Atrophy. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. Seattle (WA): University of Washington, Seattle; February 24, 2000.

    • Servais L, Finkel RS, Vlodavets D, et al; on behalf of the RAINBOWFISH Study Group. RAINBOWFISH: 2-year efficacy and safety data of risdiplam in infants with presymptomatic SMA. Presented at: Congress of the World Muscle Society (WMS), October 12, 2024; Prague, Czechia

      Servais L, Finkel RS, Vlodavets D, et al; on behalf of the RAINBOWFISH Study Group. RAINBOWFISH: 2-year efficacy and safety data of risdiplam in infants with presymptomatic SMA. Presented at: Congress of the World Muscle Society (WMS), October 12, 2024; Prague, Czechia

    • An open-label study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy. Clinicaltrials.gov. Accessed May 13, 2025. https://clinicaltrials.gov/​study/​NCT03779334

      An open-label study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy. Clinicaltrials.gov. Accessed May 13, 2025. https://clinicaltrials.gov/​study/​NCT03779334

    • De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856.

      De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842-856.

    • Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381-1389.

      Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381-1389.

    • Chiriboga CA, Bruno C, Duong T, et al; on behalf of the JEWELFISH Study Group. Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: An interim analysis from the JEWELFISH study. Neurol Ther. 2023;12(2):543-557.

      Chiriboga CA, Bruno C, Duong T, et al; on behalf of the JEWELFISH Study Group. Risdiplam in patients previously treated with other therapies for spinal muscular atrophy: An interim analysis from the JEWELFISH study. Neurol Ther. 2023;12(2):543-557.

    • Oskoui M, Day JW, Deconinck N, et al. SUNFISH Parts 1 and 2: 4-year efficacy and safety of risdiplam in types 2 and 3 spinal muscular atrophy (SMA). Presented at: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; March 19-22, 2023; Dallas, TX.

      Oskoui M, Day JW, Deconinck N, et al. SUNFISH Parts 1 and 2: 4-year efficacy and safety of risdiplam in types 2 and 3 spinal muscular atrophy (SMA). Presented at: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference; March 19-22, 2023; Dallas, TX.

    • IND Application Reporting: Safety Reports. U.S. Food & Drug. Accessed May 13, 2025. https://www.fda.gov/​drugs/​investigational-new-drug-ind-application/​ind-application-reporting-safety-reports

      IND Application Reporting: Safety Reports. U.S. Food & Drug. Accessed May 13, 2025. https://www.fda.gov/​drugs/​investigational-new-drug-ind-application/​ind-application-reporting-safety-reports

    • Nascimento A, Day JW, Deconinck N, et al; on behalf of the SUNFISH Working Group. SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Presented at: Congress of the World Muscle Society (WMS); September 20-24, 2021; Virtual.

      Nascimento A, Day JW, Deconinck N, et al; on behalf of the SUNFISH Working Group. SUNFISH Part 2: 24-month efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Presented at: Congress of the World Muscle Society (WMS); September 20-24, 2021; Virtual.

    • Kletzl H, Heinig K, Jaber B, et al. Bioequivalence and food effect assessment for a room-temperature stable risdiplam tablet formulation in healthy volunteers. Presented at: Muscular Dystrophy Association Clinical and Scientific Conference; March 3-6, 2024; Orlando, FL.

      Kletzl H, Heinig K, Jaber B, et al. Bioequivalence and food effect assessment for a room-temperature stable risdiplam tablet formulation in healthy volunteers. Presented at: Muscular Dystrophy Association Clinical and Scientific Conference; March 3-6, 2024; Orlando, FL.

    • Evrysdi® (risdiplam) Instructions For Use. Genentech, Inc.

      Evrysdi® (risdiplam) Instructions For Use. Genentech, Inc.

    • Coşkun MB, Yalçın İ, Özarslan C. Physical properties of sweet corn seed (Zea mays saccharata sturt.). J Food Eng. 2006;74(4):523-528.

      Coşkun MB, Yalçın İ, Özarslan C. Physical properties of sweet corn seed (Zea mays saccharata sturt.). J Food Eng. 2006;74(4):523-528.

    • Pharmaceutical issues when crushing, opening or Splitting Oral Dosage Forms. Royal Pharmaceutical Society. Accessed May 13, 2025. https://www.rpharms.com/​Portals/​0/​RPS%20document%20library/​Open%20access/​Support/​toolkit/​pharmaceuticalissuesdosageforms-(2).pdf.

      Pharmaceutical issues when crushing, opening or Splitting Oral Dosage Forms. Royal Pharmaceutical Society. Accessed May 13, 2025. https://www.rpharms.com/​Portals/​0/​RPS%20document%20library/​Open%20access/​Support/​toolkit/​pharmaceuticalissuesdosageforms-(2).pdf.

    • Evrysdi® (risdiplam) Instructions For Constitution. Genentech, Inc.

      Evrysdi® (risdiplam) Instructions For Constitution. Genentech, Inc.